

## 1<sup>st</sup> SCA Global Conference DRAFT Schedule as of 11-30-18

### Wednesday, March 27, 2019

8:15 - 8:20 a.m.	Welcome	Tetsuo Ashizawa, M.D.
8:20 - 8:40 a.m.	Opening Keynote Lecture Scientific premise for treatments of polyglutamine SCAs	Henry L. Paulson, M.D., Ph.D.

#### Theme 1 Existing cohorts and natural history of SCAs

	Chairs: Thomas Klockgether, M.D., Tetsuo Ashizawa, M.D.	
8:40 - 9:20 a.m.	Keynote: Enroll-HD	Bernhard Landwehrmeyer, M.D.
9:20 - 9:40 a.m.	SCAs in Europe	Thomas Klockgether, M.D.
9:40 -10:00 a.m.	READISCA	Tetsuo Ashizawa, M.D.
10:00 -10:20 a.m.	SCA3 in Brazil	Laura Jardim, M.D., Ph.D.
10:20 -10:50 a.m.	<b>Morning break</b>	
10:50 -11:10 a.m.	SCAs in Australia	
11:10 -11:30 a.m.	Taiwanese SCA cohorts	Bin-Weng Soong, M.D., Ph.D.
11:30 -11:50 a.m.	Chinese SCA	Hoang Jiang, M.D., Ph.D.
11:50 -12:10 a.m.	SCAs in Japan	Hidehiro Mizusawa, M.D., Ph.D.
12:10 - 12:30 p.m.	3 junior investigators' presentations (10 min each)	
12:30 noon - 1:30 p.m.	<b>Lunch</b>	

#### Theme 2 Common standards for clinical assessment, brain imaging and biosampling

	Chairs:	Christopher Gomez, M.D., Ph.D., Gulin Oz, Ph.D.
1:30 - 2:10 p.m.	Keynote: Fluid biomarkers	TBD
2:10 - 2:30 p.m.	Magnetic resonance biomarkers	Gulin Oz, Ph.D.
2:30 - 2:50 p.m.	Clinical scales and functional tests	Alexandra Dürr, M.D., Ph.D.
2:50 - 3:10 p.m.	ENIGMA	Ian Harding, M.D.
3:10 - 3:40 p.m.	<b>Afternoon break</b>	
3:40 - 4:00 p.m.	Wearable sensors to measure ataxia	Christopher Gomez, M.D., Ph.D.
4:00 - 4:20 p.m.	NIH's interest	Daniel Miller, Ph.D.
4:20 - 4:40 p.m.	Industry's perspective	Ludy Shih, Ph.D.
4:40 - 5:10 p.m.	3 junior investigators' presentations (10 min each)	
5:10 - 6:00 p.m.	Panel Discussion	
6:00 - 7:30 p.m.	<b>Social Reception (Tentative)</b>	

**Thursday, March 28, 2019**

Theme 3 Enhancing clinical trial readiness

Chair: Alexandra Durr, M.D., Ph.D.

8:30 - 8:50 a.m.	Keynote: Clinical trials in HD	TBD
8:50 - 9:10 a.m.	Trial design	Sophie Tezenas du Montcel, Ph.D.
9:10 - 9:30 a.m.	Biomarker/outcome measure certification and drug approval	FDA
9:30 - 9:50 a.m.	Regulatory requirements for resource sharing	NIH/EU

9:50 - 10:20 a.m. **Morning break**

10:20 - 10:50 a.m. Panel Discussion  
10:50 a.m. -12:30 p.m. Presentations of selected abstracts

12:30 a.m. - 1:30 p.m. **Lunch**

Working groups (parallel sessions)

1:30 - 1:45 p.m.	Defining tasks of working groups
1:45 - 2:00 p.m.	Charging each working group for specific goals
2:00 - 5:30 p.m.	Group sessions

Working Group Leaders

Clinical outcome	Thomas Klockgether, M.D.
MR Biomarkers	Gulin Oz, Ph.D.

**Friday, March 29, 2019**

Continental breakfast from AAC

8:30 - 9:00 a.m. Group Photo

Plenary session (with presentation of working group results) Chair: Holm Graeßner, Ph.D., MBA

9:00 - 9:30 a.m.	Clinical outcome	Thomas Klockgether, M.D.
9:30 - 10:00 a.m.	MR biomarkers	Gulin Oz, Ph.D.
10:00 - 10:30 a.m.	Standard of biosampling	Thomas Klockgether, M.D.
10:30 - 10:45 a.m.	Data sharing/Regulatory requirements	Holm Graeßner, Ph.D., MBA
10:45 - 11:00 a.m.	Action plans and closing remark	Alexandra Durr, M.D., Ph.D.

Joint meeting with the NAF Annual Conference participants

11:00 - 11:30 a.m.	SCA Global and lay summary of the conference	Thomas Klockgether, M.D.
11:30 - 12:00 noon	Questions and Answers	